PubHealth.info® (An Information Portal on Public Health Issues / Topics, Presented in Collaboration with PakMed Biomedical Solutions)

[PubHealth.info Homepage] [Category Homepage] [Disclaimer/Copyrights] [Feedback]


Thank you for your kind visit to PubHealth.info®, an information portal created in technical collaboration with PakMed Biomedical Solutions * * * PubHealth.info® presents hundreds of thousands of informative Web pages on a variety of public health issues / issues * * * An ultimate source of information for teachers, students and research workers who need to find information on various public health issues, like population planning, contraception, HIV AIDS, STDs, maternal and child health, communicable and non-communicable disease, etc. * * * PubHealth.info® regularly updates the repository of these hundreds of thousands of informative Web pages * * * PubHealth.info® is one of the world's largest repositories and information portals with online Web pages on public health issues particularly those pertaining to developing countries!

PubHealth.info® (a subsidiary of PakMed) presents scientific information mainly based on abstracts of articles published on a variety of public health issues/topics, particularly encompassing population planning, disease prevention, maternal and child health, and communicable and non-communicable diseases (like HIV AIDS, malaria, etc) that are affecting a significant portion of population in developing and developed countries. Here you can find abstracts of articles published on a variety of public health topics under category "Contraception (Birth Control) and Family Planning". Contraception (birth control) is a regimen of one or more actions, devices, or medications followed in order to deliberately prevent or reduce the likelihood of a woman becoming pregnant or giving birth. Therefore contraception is the utilization of various and sundry surgical procedures, devices, practices, agents, or drugs with the intention of preventing conception or impregnation (pregnancy). Methods and intentions typically termed birth control may be considered a pivotal ingredient to family planning. Birth control is a controversial political and ethical issue in many cultures and religions, and although it is generally less controversial than abortion specifically.

Here you can find more than 42,000 article titles on "Contraception (Birth Control) and Family Planning" , along with their abstracts and bibliographic information (one of the world's largest collections of article titles on this topic), mentioned in various lists that are sorted/arranged according to the years of publication. You can view the bibliographic details and abstracts of these articles, by clicking the title of your required article. To view other lists of articles in the same category "Contraception (Birth Control) and Family Planning", please visit "Category Lists Homepage" or select a list from the following dropdown list of article titles.

 

List 29: Articles 14001-14500 (500 Articles)

To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles
  1. Recommendations of the Zurich Conference on oral contraception. [Empfehlungen des "Zurcher Gesprachskreises" zur oralen Kontrazeption.]
  2. Reduced oral contraceptive effectiveness with concurrent antibiotic use: a protocol for prescribing antibiotics to women of childbearing age.
  3. Reduction of the risk of rheumatoid arthritis among women who take oral contraceptives.
  4. Reflections on the importance of new progestagens in the prevention of cardiovascular side effects of combined estrogen-progestagen oral contraceptives. [Reflexions sur l'interet des nouveaux progestatifs dans la prevention des effets secondaires cardio-vasculaires des pilules contraceptives oestro-progestatives.]
  5. The regional dimensions of family planning and fertility decline in Indonesia.
  6. Regional program for widespread screening for Chlamydia trachomatis in family planning clinics.
  7. Relationship between contraceptive technology and HIV transmission: an overview.
  8. The relationship between fertility and contraceptive prevalence in Zimbabwe.
  9. The relationship between menarche and sexual, contraceptive, and reproductive life events.
  10. The relationship between oral contraceptive use, cancer and vascular disease.
  11. Relationship between premenstrual symptoms and oral contraceptive use: a controlled study.
  12. The relationship between vascular headaches and low-dose oral contraceptives.
  13. The relationship of oral contraceptive use to rheumatoid arthritis.
  14. The relationships among knowledge, perceived accessibility and practice of contraception of Mexican-American adolescent females.
  15. The relationships of contraceptive behavior and contraceptive embarrassment to identity, career maturity, and vocational identity.
  16. Relevance of immuno-contraceptive vaccines for population control. I. Hormonal immunocontraception.
  17. Report of the Subcommittee on Quality Indicators in Family Planning Service Delivery.
  18. Report on the Lesotho Planned Parenthood Association community-based distribution project evaluation.
  19. Reproductive health survey of young adults: sexual experience and use of contraceptives in Santiago, Chile. [Encuesta de salud reproductiva en adultos jovenes: experiencia sexual y uso de anticonceptivos en Santiago, Chile.]
  20. Reproductive intentions and contraceptive use: a case study of Zimbabwe.
  21. Reproductive tract infections and contraceptive use / safety.
  22. Resistance to contraception. [La resistance a la contraception.]
  23. Resource mobilization, contraceptive commodities and donor co-ordination.
  24. Respect for religion and tradition: key to family planning in Jordan.
  25. A responsibility for the whole society--how the government tackles family planning in the German Democratic Republic.
  26. Results from the Oxford-Family Planning Association study.
  27. Results from the Royal College of General Practitioners' Oral Contraception Study.
  28. Sexual experience and use of contraception among young adults in Latin America. [Experiencia sexual y uso de anticonceptivos entre los adultos jóvenes en América Latina.]
  29. Shanghai adopts family planning regulations.
  30. The significance of postcoital hormonal contraception for prevention of conception. [Die Bedeutung der postkoitalen hormonalen Kontrazeption fur die Empfangnisverhutung.]
  31. The situation analysis study of the family planning program in Kenya.
  32. Slaughter of the innocents: coercive birth control in China.
  33. Slippage in the price of voluntary contraception: hazard or necessity? [Le derapage des prix de la contraception volonte? Hasard ou necessite?]
  34. A slow gallop into the year of the horse: new legislation on family planning in the People's Republic of China. [In gebremstem Galopp ins Jahr des Pferdes: Neues Recht der Geburtenplanung in der VR China.]
  35. SMART START: impact of delaying the pelvic exam on timing of teen's first family planning visit, contraceptive use and sexually transmitted diseases (preliminary results)
  36. Social Marketing for Change (SOMARC). Contraceptive Usage and Pack Design Study (focus groups). Final report.
  37. Social Marketing of Contraceptives. A project of Government of Pakistan and USAID. Briefing book.
  38. Social Marketing of Contraceptives. A project of Government of Pakistan and USAID. Quarterly report 18, April - June, 1990.
  39. Social Marketing of Contraceptives: a project of Government of Pakistan and USAID. Quarterly report 16: October - December, 1989.
  40. Social preconditions of founding and developing the family planning movement. [Drustveni preduslovi osnivanja i razvoja pokreta planiranja porodice u svetu.]
  41. Socio-cultural factors influencing the delivery and use of health and family planning services in Senegal (with special attention to women's health)
  42. Socio-economic and cultural differentials in contraceptive usage among Ghanaian women.
  43. Sociodemographic characteristics of participants in introductory natural family planning courses: final report of a pilot study. [Soziodemographische Charakteristika von teilnehmern an Einfuhrungskursen zur naturlichen Familienplanung.]
  44. Some further consideration on the role of oral contraceptives in breast carcinogenesis.
  45. Some immediate results from the integration of family planning into health services and from contraceptive use. [Quelques resultats immediats atteints en matiere d'integration de la PF dans les services de sante et de l'utilisation des moyens contraceptifs.]
  46. Some reflections on the introduction of family planning into businesses in Cameroon. [Reflexions sur l'introduction de la planification familiale dans les entreprises au Cameroun.]
  47. Son preference and contraceptive use in Pakistan: evidence from the Pakistan Contraceptive Prevalence Survey, 1984-85.
  48. Son preference, fertility desire and contraceptive use in two largest cities of Pakistan.
  49. South Asia Conference on Population Trends and Family Planning (New Delhi, March 14-20, 1989): proceedings of the conference.
  50. Special features of triphasic oral contraceptives and their theoretical indications. [Les particularites des estroprogestatifs triphases et leurs indications theoriques.]
  51. Sperm and seminal plasma antigens relevant to contraceptive vaccine development.
  52. Spermicides, hormonal contraception and congenital malformations.
  53. In Sri Lanka, a majority of couples have talked about family planning.
  54. Statistical compendium on contraceptive prevalence and practice in African countries.
  55. Statistics on family planning and abortion in Chile. [Estadisticas sobre planificacion familiar y aborto en Chile.]
  56. The status of family planning in developing countries.
  57. The status of women and family planning acceptance: some field results.
  58. Sterilization a popular, effective method of birth control.
  59. Sterilization and contraceptive practice in Puerto Rico, 1982. [Esterilizacion y practica anticonceptiva en Puerto Rico, 1982.]
  60. A strategic approach to family planning communication in Ecuador.
  61. Strategies for family planning information, education, and communication.
  62. Strengthening collaborating institutions: the role of technical assistance in the family planning operations research program.
  63. Studies on fibrinopeptide A, fibrinopeptide B beta 15-42 and inhibitors of blood coagulation and fibrinolysis during use of oral contraceptives.
  64. Study of characteristics of condom-acceptors using condom as first choice and alternative method of contraception in 1981-1987 at the NPFDB, GHKL.
  65. Study of compensation payments and family planning in Bangladesh: a synthesis.
  66. A study of MTP acceptors and their subsequent contraceptive use.
  67. Study of rigevidon for oral contraception in a family planning clinic in Kota Bahru, Kelantan.
  68. A study of the acceptability and effectiveness of Norplant (R) contraceptive implants in Kuala Lumpur, Malaysia.
  69. A study of utilisation of family planning services through MCH package care in rural areas of West Bengal.
  70. Study on integration of family planning and essential drugs in Kenya.
  71. A study on the current contraceptive acceptors' unwanted pregnancy experience. Summary.
  72. Summaries of family planning operations research studies. Draft.
  73. Summary of proceedings, Consultative Meeting on the Philippine Family Planning Program, 12-13 July 1990.
  74. Summary of Twentieth National Survey on Family Planning.
  75. Support by governments for birth control rose over the past 15 years.
  76. Surgical sterilization and health practices in birth control policy (letter) [A muvi meddove tetel es az egeszsegkultura a szuleteskorlatozasban.]
  77. Sustainability and cost effectiveness of FPPS subprojects. Final report submitted to Family Planning Private Sector Project.
  78. Sustained-release contraceptives.
  79. Tailoring contraceptives to human needs.
  80. The taming of sex: Jeanne Humbert and the struggle for birth control. [Le sexe apprivoise: Jeanne Humbert et la lutte pour le controle des naissances.]
  81. Technical cooperation in family planning program.
  82. Testosterone and sexual behavior in oral contraceptive users and nonusers: a prospective study.
  83. Thoughts on progestational contraception. [Reflexions sur la contraception progestative.]
  84. Time varying period codings: a method of assessing the effect of family planning programs on fertility.
  85. The Title X family planning subsidies: the government's role in moral issues.
  86. Toward a new standard in oral contraception: Proceedings of a symposium held at the XIII World Congress on Fertility and Sterility, Marrakesh, Morocco, October 3, 1989.
  87. Toward a policy, national programme and strategies in maternal and child health / family planning. Consensus = Building Seminar for Decision Makers. Original papers. [Vers une politique, programme national et strategies en matiere de la sante maternelle et infantile / planning familial. Seminaire - atelier de recherche de consensus pour les decideurs. Presentations originales.]
  88. Towards healthy family planning attitude: a self persuasion approach.
  89. Traditional contraceptive use in Sri Lanka: a cross survey analysis.
  90. Training family planning program managers for the Year 2000.
  91. Training in maternal-child health / family planning.
  92. Training of personnnel in the field of family planning.
  93. Transdermal delivery of contraceptives.
  94. Treatment of hirsutism related to micropolycystic ovary syndrome (MPCO) with two low-dose oestrogen oral contraceptives: a comparative randomized evaluation.
  95. Trip report, Ghana. Private Sector Midwives and Family Planning Project, Grant No: 641-0462-G-SS-7024-00. April 20 - June 10, 1990.
  96. Trip report: countering rumors on family planning in Bangladesh. Report on an observational study conducted for JHU/PCS.
  97. Two-year carbohydrate metabolism studies in women using a norethindrone or levonorgestrel triphasic oral contraceptive.
  98. U.S. approves contraceptives planted in skin.
  99. The unfinished demographic transition: family planning in the 1990s.
  100. Unmet need and nonuse of family planning in Botswana.
  101. Unwanted pregnancy and family planning needs in Latin America and the Caribbean.
  102. Update of the Los Angeles Study of oral contraceptives and breast cancer: 1981 and 1983.
  103. Update of the Swedish - Norwegian case-control study on oral contraceptive use and breast cancer in young women: the possible role of bias.
  104. Update on cancer risk and oral contraceptives.
  105. Update on combination oral contraceptives.
  106. Update on lipid metabolism and oral contraception.
  107. Use of a monthly calendar for collecting retrospective data on contraception: an evaluation of the DHS experimental field studies.
  108. Use of contraception and family planning services in the United States, 1988.
  109. Use of contraceptive methods in the adolescent population. [Uso de metodos anticonceptivos en poblacion adolescente.]
  110. Use of family planning services in the United States: 1982 and 1988.
  111. The use of log-linear models for the analysis of family planning in West Java. [Model log-linear dalam analisis data keluarga berencana di Jawa Barat.]
  112. Use of oral contraceptives in relation to dietary habits and alcohol consumption.
  113. Use of the stable nitrogen isotope 15N in assessing liver metabolism in hormonal contraception.
  114. Using the Luker model to explain contraceptive use among adolescents.
  115. Utilization of research findings for the improvement of family planning programmes: implications for IE and C.
  116. Vascular complications in women using the low steroid content combined oral contraceptive pills: case reports and review of the literature.
  117. The view of a family planning doctor on the long-term use of oral contraceptives in young women.
  118. Viscoelasticity of whole blood as a function of age, gender, cigarette smoking and intake of oral contraceptives.
  119. Ways of surveying the demand for family planning services. [Cara mengukur permintaan pelayanan keluarga berencana.]
  120. What conclusions can we reach and how do we best assist women to make informed choices regarding their use of oral contraceptives.
  121. What is current use of a contraceptive method?
  122. What oral contraception and for whom? [Quelle contraception orale et pour qui?]
  123. When teens don't wait: encouraging contraception.
  124. Which are the commonest questions about contraceptives and how shall we answer them? [Vilka ar de vanligaste fragorna om p-piller och hur skall vi besvara dem?]
  125. Will the anesthetist become, in the obstetrical environment, a new family planning decision maker? [L'anesthesiste sera-t-il demain, en milieu obstetrical, un nouveau decideur en matiere de planning familial?]
  126. Woman's body, woman's right. Birth control in America. Revised and updated.
  127. Women need skills, income and family planning.
  128. Women's interests: how can family planning managers respond?
  129. Women's involvement in community development: the story of Korea's Family Planning Mothers' Club.
  130. Women's right to contraception: the road to achievement.
  131. Workshop on Contraceptive Quality Assurance, Bangkok, Thailand, January 15 - February 5, 1990.
  132. Younger Jordanian husbands more often favor family planning, joint spousal decision-making.
  133. Younger Jordanian husbands more often favor family planning, joint spousal decision-making.
  134. Zaire. Family Planning Services Project: technical support mission.
  135. Zaire. Family Planning Services Project: technical support mission.
  136. Barrier methods of contraception and the risk of cervical neoplasia.
  137. The behavior of cytoplasmic progesterone receptors in the cycling endometrium and the effect of hormonal contraceptives. [Das Verhalten der zytoplasmatischen Progesteronrezeptoren im zyklischen Endometrium und unter der Einwirkung hormonaler Kontrazeptiva.]
  138. Bioequivalence of two oral contraceptive drugs containing norethindrone and ethinyl estradiol.
  139. A boost for family planning.
  140. Breast cancer and oral contraceptives [letter]
  141. Cancer of the breast and reproductive tract in relation to use of oral contraceptives.
  142. Carbohydrate metabolic studies during twelve months of treatment with a low-dose combination oral contraceptive.
  143. Interobserver variation in estimation of day of conception intercourse using selected natural family planning charts.
  144. Investigating the social context of fertility and family planning: a qualitative study in Peru.
  145. Knowledge of reproductive physiology and modern contraceptives in rural Peru.
  146. Laparoscopic removal of translocated intrauterine contraceptive devices.
  147. Oral contraceptives: effect of long-term use on liver vitamin A storage assessed by the relative dose response test.
  148. Organizing community participation in family planning projects in South Asia.
  149. Pharmacodynamics of a contraceptive vaginal ring releasing 3-keto-desogestrel.
  150. Pharmacology of contraceptives steroids: a brief review.
  151. Analysis of motivation to contraceptive use applying the weighting procedure.
  152. Antibody response and characteristics of antibodies in women immunized with three contraceptive vaccines inducing antibodies against human chorionic gonadotropin.
  153. Antisperm antibodies in young oral contraceptive users.
  154. Assessing behavioral risk for HIV infection in family-planning and STD clinics: similarities and differences.
  155. Attitudes toward voluntary surgical contraception in four districts of Kenya.
  156. Cervical adenocarcinomas during and after longterm hormonal contraceptive use. [Adenokarzinome der Cervix uteri bei Patientinnen mit einnahme hormonaler kontrazeptiva.]
  157. Changing patterns of fertility and the supply of contraceptive commodities.
  158. Clinical evaluation of a new combined oral contraceptive, desogestrel-ethinylestradiol.
  159. Clinical evaluation of the Capronor contraceptive implant: preliminary report.
  160. Clinical evaluation of two monthly injectable contraceptives and their effects on some metabolic parameters.
  161. A clinical overview of a new triphasic contraceptive containing gestodene.
  162. Clinical performance of a levonorgestrel-releasing intracervical contraceptive device during the first two years of use.
  163. Collection of survey data on contraception: an evaluation of an experiment in Peru.
  164. Combination of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraception.
  165. Combined oral contraceptives and gallbladder cancer.
  166. A comparative analysis of three different dose combinations of oral contraceptives.
  167. A comparative evaluation of the safety and contraceptive effectiveness of 65 mg and 100 mg of 90-day norethindrone (NET) injectable microspheres: a multicenter study.
  168. Comparative trial between two soft jelly capsules containing nonoxynol as spermicidal contraceptives.
  169. Comparison of two monophasic oral contraceptives: gestodene / ethinyl estradiol versus desogestrel / ethinyl estradiol.
  170. Condom use and patterns of sexual behaviour among sexually experienced women attending family planning clinics in England, Scotland and Wales.
  171. Consensus statement on the use of breastfeeding as a family planning method, Bellagio, Italy, August 1988.
  172. Contraceptive efficacy of norethindrone encapsulated in injectable biodegradable poly-dl-lactide-co-glycolide microspheres: phase II clinical study.
  173. Contraceptive failure in the United States: revised estimates from the 1982 National Survey of Family Growth.
  174. Contraceptive method change among rural Sri Lankan women.
  175. Contraceptive method choice in the Philippines, 1973-83.
  176. Contraceptive method switching over women's reproductive careers: evidence from Malaysian life history data, 1940s-70s.
  177. Contraceptive prevalence and continuation: a longitudinal analysis of traditional and other method users in the Philippines.
  178. The contraceptive sponge: factors in initiation and discontinuation of use.
  179. Contraceptive switching among currently married women in the United States.
  180. Correcting misconceptions about oral contraceptives.
  181. Determinants of contraceptive use dynamics: research needs on decision and choice.
  182. Dynamic behavioural models and contraceptive choice.
  183. Effect of Norplant contraceptive use on hemoglobin, packed cell volume and menstrual bleeding patterns.
  184. Effect of oral contraceptives or dexamethasone on plasma beta-endorphin during the menstrual cycle.
  185. The effect of triphasic oral contraceptives on plasma lipids and lipoproteins.
  186. Effect of two monophasic oral contraceptives containing gestodene or desogestrel on serum lipoprotein lipid levels.
  187. The effects of a progestin-only oral contraceptive (levonorgestrel 0.03 mg) on breast-feeding.
  188. The effects of breastfeeding and contraception on the natural rate of increase: are there compensating effects?
  189. Effects of low-dose oral contraceptives on sugar metabolism. [Effetti dei contraccettivi orali a basse dosi sul metabolismo glucidico.]
  190. The effects of oral contraceptives on reproduction.
  191. Effects of smoking and oral contraception on plasma B-carotene levels in healthy women.
  192. Effects of two triphasic oral contraceptives containing ethinylestradiol plus levonorgestrel or gestodene on blood coagulation and fibrinolysis.
  193. Elevated plasma levels of oxytocin in women taking low-dose oral contraceptives. Identification of the plasma oxytocin with high performance liquid chromatography.
  194. Epithelial ovarian cancer and combined oral contraceptives. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
  195. Estrogen-progestogen once-a-month injectable contraceptives and serum prolactin.
  196. Evaluating triphasic oral contraceptives: the rationale for a randomized trial.
  197. Evaluation of the clinical performance of three triphasic oral contraceptives: a multicenter, randomized comparative trial.
  198. An evaluation of the cost-effectiveness of mobile family planning services in Tunisia.
  199. Factors associated with use of the contraceptive sponge.
  200. Family planning in Burkina Faso: results of a survey.
  201. Family planning policy and practice in China: a study of four rural counties.
  202. Family planning programmes in ten developing countries: cost effectiveness by mode of service delivery.
  203. Fertility policy and family planning in the Arab countries.
  204. Gestational trophoblastic disease and use of oral contraceptives [letter]
  205. Health care provider and contraceptive care setting: the relationship to contraceptive behavior.
  206. Hemorheological effects of oral contraceptives.
  207. The importance of ultrasonography in infertile women with "forgotten" intrauterine contraceptive devices.
  208. The incidence of malformations after use of hormonal contraceptives. [Fehlbildungshaufigkeit nach Anwendung hormonaler Kontrazeptiva.]
  209. The incremental cost of screening, diagnosis, and treatment of gonorrhea and Chlamydia in a family planning clinic.
  210. The influence of a combined oral contraceptive on uterine activity and reactivity to agonists in primary dysmenorrhea.
  211. Influence of the number of living sons on contraceptive use among female teachers in Nigeria.
  212. Inhibition of ovulation by a new low-dose monophasic contraceptive containing gestodene.
  213. Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: a controlled, comparative, 12-month clinical trial.
  214. Long-acting steroidal contraception: an update.

     

  215. Longitudinal ultrasonographic study of the ovarian suppressive activity of a low-dose triphasic oral contraceptive during correct and incorrect pill intake.
  216. Luteinizing hormone releasing hormone agonist for contraception in breast feeding women.
  217. Male knowledge, use and attitudes regarding family planning in Burkina Faso.
  218. Men's attitudes about family planning in Dakar, Senegal.
  219. Monthly injectable steroid contraceptives and cervical carcinoma.
  220. Mortality among oral contraceptive users: 20 year follow up of women in a cohort study.
  221. A multicentred phase III comparative study of two hormonal contraceptive preparations given once-a-month by intramuscular injection. II. The comparison of bleeding patterns.
  222. Myocardial infarction in young women with reference to oral contraceptive use.
  223. Noncontraceptive clinical benefits of oral contraceptives.
  224. Norplant contraceptive subdermal implants: two-year experience in Singapore.
  225. Norplant: subdermal implant system for long-term contraception.
  226. Oral contraceptive use and breast cancer risk in young women.
  227. Oral contraceptive use and liver cancer.
  228. Oral contraceptive use and premenopausal breast cancer in Sweden and Norway: possible effects of different pattern of use.
  229. Oral contraceptives and breast cancer [letter]
  230. Oral contraceptives and breast cancer: results from an expanded case-control study.
  231. Oral contraceptives and lipids and lipoproteins: Part I --variations in mean levels by oral contraceptive type.
  232. Oral contraceptives in relation to cancer of the breast and reproductive tract--an epidemiological review.
  233. Plasma reduced and total ascorbic acid in healthy women: effects of smoking and oral contraception.
  234. Post-coital contraception: an overview of published studies.
  235. Postcoital contraception: a family planning study.
  236. The relationships of SHBG with current and previous use of oral contraceptives and oestrogen replacement therapy.
  237. The reliability of surrogate information about oral contraceptive use, smoking, height and weight collected from men about their wives.
  238. Reply [to Hernandez comment on "Measuring Components of Family Planning Program Effort"]
  239. Safety of oral contraceptives related to steroid content: a critical review.
  240. Serum levels of pregnancy-associated endometrial alpha 2-globulin (alpha 2-PEG) during normal menstrual and combined oral contraceptive cycles and relationship to immunohistological localization.
  241. Sexual activity, contraception, genital infections, and cervical cancer: support for a sexually transmitted disease hypothesis.
  242. Sexual behavior and contraceptive use by adolescent pupils in the Republic of Bophuthatswana.
  243. Sexual behavior, contraception and unintended pregnancy among young females.
  244. Sexual behaviour and attitudes to barrier contraception among family planning clinic attenders.
  245. STD and contraception in adolescents.
  246. A study of the vaginal contraceptive sponge used with and without the fertility awareness method.
  247. A system for monitoring hormonal contraceptive care in general practice.
  248. Toward family planning in the 1990s: a review and assessment.
  249. Use of multiphasic oral contraceptives and hospitalizations of women with functional ovarian cysts in the United States.
  250. The vaginal contraceptive diaphragm and the condom: a reevaluation and comparison of two barrier methods with the rhythm method.
  251. Villages as contexts for contraceptive behavior in rural Egypt.
  252. The WHO multicentre trial of the vasopressor effects of combined oral contraceptives: 1. comparisons with IUD.
  253. The WHO multicentre trial of the vasopressor effects of combined oral contraceptives: 2. lack of effect of estrogen.
  254. The worldwide use of steroidal contraception.
  255. Pharmacists and family planning./El farmaceutico y la planificacion familiar./Les pharmaciens et le planning familial.
  256. Lights! Camera! Action! Promoting family planning with TV, video, and film./Luz! Camera! Accion! Como fomentar la planificacion familar mediante la television, videos y peliculus./Lumière ! On tourne ! La tele, la video et le film au service du planning familial.
  257. Barrier contraception. [Anticonceptivos de barrera.]
  258. Barrier contraceptives.
  259. The benefits and costs of family planning services.
  260. The benefits of combined oral contraceptives.
  261. Better communication makes a difference in use of family planning -- the Turkish experience.
  262. The biochemistry of oral contraceptive steroids.
  263. Biomedical issues in family planning in Africa.
  264. Birth control and declining birth rates: the Bulgarian experience.
  265. Birth control and religion.
  266. Birth control as innovation in Stavanger, 1900-1935. [Barnebegrensing som innovasjon i Stavanger 1900-1935.]
  267. Birth control in the Netherlands, 1982 and 1988. [Geboortenregeling in Nederland, 1982 en 1988.]
  268. BKKBN and the expanding role of private sector FP services and commercial contraceptive sales in Indonesia.
  269. Breast cancer and combined oral contraceptives: an Italian case-control study.
  270. Breast cancer and oral contraceptives: patterns of risk among parous and nulliparous women -- further analysis of the Swedish-Norwegian material.
  271. Breast cancer before age 45 and oral contraceptive use: new findings.
  272. Breast feeding -- a contraceptive? [editorial]
  273. Breastfeeding and family planning programs: a vital complementarity.
  274. Breastfeeding and family planning programs: a vital complementarity.
  275. Breastfeeding: the oldest method of female contraception. [La lactancia materna. El metodo mas antiguo de la anticoncepcion femenina.]
  276. Burkina Faso: Baseline Survey of Knowledge, Attitudes and Practice of Family Planning in Two Provinces: Kenedougou and Zoundweogo-Burkina Faso, March - May 1989.
  277. Cabinet decision creating a family planning section in the Ministry of Manpower, 1989.
  278. Cabinet decision creating a family planning section in the Ministry of Manpower.
  279. Caffeine, oral contraceptives, and over-the-counter drugs [letter]
  280. Caffeine, oral contraceptives, and over-the-counter drugs. In reply [letter]
  281. Can natural family planning really work?
  282. Can we justify the giving of family planning services by nonmedical personnel]? [Comment justifier la prestation des services des naissances desirables par le personnel non medical.]
  283. Cancer risks of oral contraception.
  284. Carbohydrate and lipid metabolism in low-dose oral contraception.
  285. Integration and home visiting: necessary ingredients for acceptance of family planning services in indigenous communities? Results from an experiment in Ecuador.
  286. Intensifying family planning policy, promoting population control.
  287. Interactions between carbamazepine and birth control pills [letter]
  288. International family planning policy--a chronicle of the Reagan years [Draft]
  289. International workshop report: Counselling and HIV Infection for Family Planning Associations, 13-17th March, 1989.
  290. The interrelationship between oral contraceptives and infections of the female reproductive tract.
  291. Interval insertion of an intrauterine contraceptive device following cesarean section.
  292. Introducing family planning services as part of primary health care in the Diourbel region: final report. [Lancement des services de planification familiale comme composante des services de soins de sante primaires dans la region de Diourbel, rapport final.]
  293. Introducing new contraceptive technologies in developing countries.
  294. Inventory of family planning training materials.
  295. Investing in reduced population growth: costs of delivering family planning in the 1990's.
  296. IPPF statement on oral contraceptives and cancer of the breast.
  297. Is it really necessary to discontinue hormonal contraceptives before carrying out a planned operation? [Ist es wirklich erforderlich, hormonale Kontrazeptiva vor der Durchfuhrung einer geplanten Operation abzusetzen?]
  298. Is it safe to prescribe hormonal contraception and replacement therapy to patients with premalignant and malignant uterine cervices?
  299. Is the Chinese family planning program "tightening up"?
  300. Is there an increased risk of twinning after discontinuation of the oral contraceptive pill?
  301. Islam and family planning.
  302. IUD litigation: the Planned Parenthood experience.
  303. IUDs are contraceptives, not abortifacients: a comment on research and belief.
  304. Jaundice caused by oral contraceptives, pregnancy cholestasis and elevation of transaminases (letter) [Ictere sous contraceptif oral, cholestase gravidique et elevation des transaminases.]
  305. Journalism and family planning in Guinea-Bissau. Putting the accent on birth spacing. [Journalisme et planification familiale en Guinee-Bissau. Mettre l'accent sur l'espacement des naissances.]
  306. Keynote address. The history of steroidal contraception: what is past and what is present?
  307. Kilusang lalaki para sa maunlad na pamayanan. (Using Male Motivators to Generate Demand for Family Planning in a Male Farmer Organization). A mid-term report.
  308. Knowledge of AIDS, sexual behavior and condom use in the context of AIDS prevention, results of the 1988 survey of Contraceptive Prevalence and K-A-P for AIDS in Kinshasa, Zaire.
  309. Knowledge, attitude and practice of contraception (family planning methods) among teenagers in South Nyanza District, Kenya.
  310. Lack of association between oral contraceptive use and Crohn's disease: a community-based matched case-control study.
  311. Lack of empathy and information cited as barriers to wider contraceptive use in a traditional community.
  312. Lagos market-based family planning project, final report.
  313. The legal position regarding contraceptive advice and provision to young people.
  314. Lessons from family planning and their application to AIDS prevention.
  315. Lessons from family planning programs.
  316. Oral contraceptives: adverse reactions in internal medicine. [Orale Kontrazeptiva: unerwunschte Wirkungen im Bereich der inneren Medizin.]
  317. Oral contraceptives: significance of their effects in man and relationship to findings in animal models.
  318. Organization and implementation of China's national sampling survey on fertility and birth control.
  319. Organon contribution to family planning, 4th ed.
  320. Our experience in using the triphasic contraceptive trisiston for contraception. [Nashiiat opit ot prilozhenieto na trifazniia kontratseptiv trisiston za kontratseptsiia.]
  321. Our knowledge of drug interactions with oral contraceptives.
  322. Outcome of pregnancy in users of natural family planning.
  323. Ovarian cysts and oral contraceptives [letter]
  324. Ovarian cysts and oral contraceptives. Reply [letter]
  325. Ovarian follicles during oral contraceptive cycles: their potential for ovulation.
  326. Overall fertility impact of new contraceptive methods may be limited.
  327. Overview of commonly-practiced birth control methods.
  328. Ovral as a "morning-after" contraceptive.
  329. Paget-Schroetter syndrome in a patient on the contraceptive pill [letter]
  330. Panafrican Project on Printed Aids in Family Planning. [Projet Panafricain de Supports Imprimes en Matiere de Planification Familiale.]
  331. Pancreatic islet cell function in oral contraception, pregnancy and lactation -- a review.
  332. Parental sex preference and its effects on fertility intention and contraceptive use in Calcutta.
  333. Patient flow analysis: a technique for improving quality of service delivery in family planning clinics in Ecuador.
  334. Pattern of family planning performance in relation to socio-economic development at the state level.
  335. Patterns in fertility and contraceptive use in Addis Ababa: a follow-up survey among family planning acceptors.
  336. Pelvic inflammatory disease and the intrauterine contraceptive device.
  337. Personal fears and perceptions: implications for family planning policies.
  338. Pharmacokinetics of norethisterone from two different combination contraceptive pills in Indian women.
  339. The pharmacologic and metabolic effects of oral contraceptives.
  340. Philippine National Inventory / Baseline Survey on Family Welfare / Family Planning Programs at the Workplace.
  341. Photonovels and comic books for family planning. [Information packet]
  342. Physicians' perceptions of contraceptive methods: cultural comparisons.
  343. Planned parenthood as a constitutional right.
  344. The Planned Parenthood Association of Southern Africa.
  345. 10 years after compulsory sterilization: women are the key figures in Indian family planning. [Tio ar efter tvangssteriliseringarna: kvinnorna nyckelfigurer i indisk familjeplanering.]
  346. 1988 annual report: Family Planning International Assistance.
  347. 1989 Jamaica Contraceptive Prevalence Survey: final report.
  348. Abortion and birth control methods in youths. [Nuorten abortit ja ehkaisymenetelmat.]
  349. Abortion, birth control and surrogate parenting: an Islamic perspective.
  350. Abstracts of papers prepared for the seminar on the Role of Family Planning Programmes as a Fertility Determinant sponsored by the International Union for the Scientific Study of Population [IUSSP], Committee on the Comparative Analysis of Family Planning and Fertility, June 26-30, 1989, Tunis, Tunisia.
  351. Accelerating family planning acceptance in Rwanda: results of an operations research project.
  352. Access to health and family planning services in rural Uttar Pradesh: a micro-level evaluation.
  353. Accessibility as a determinant of contraceptive method choice.
  354. Acute myocardial infarct in a 14-year-old girl treated with contraceptives. Coronary arteriography and immediate thrombolytic therapy. [Infarto miocardico acuto in quattordicenne in trattamento contraccettivo. Arteriografia coronarica e terapia trombolitica immediata.]
  355. Administrative project on the quality of care in the provision of family planning services. [Proyecto administrativo sobre calidad de atencion en la provision de servicios de planificacion familiar.]
  356. Adolescent contraception: nonhormonal methods.
  357. Adolescent contraceptive use and parental notification.
  358. The adolescent heterosexual relationship and its association with the sexual and contraceptive behavior of black females.
  359. Advances in contraception.
  360. Advantages and inconveniences of community distribution of contraceptives: technical and administrative problems with the community distribution of contraceptives found in Kasai-Oriental. [Avantages et inconvenients de la distribution communautaire des contraceptifs: problemes techniques et administratifs dans les distributions communautaires de contraceptifs rencontres au Kasai-Oriental.]
  361. Agency leads in family planning assistance.
  362. Aggregate and lifetime contraceptive failure in the United States.
  363. AIDS and family planning in developing countries.
  364. AIDS knowledge, perceived risk and prevention among adolescent clients of a family planning clinic.
  365. AIDS risk among women with multiple sexual partners: screening data from a family planning population.
  366. AIDS, sex and family planning: a Christian view.
  367. Analysis of contraceptive method choice and optimum contraceptive pricing structures.
  368. Analysis of participant reactions to a series of family planning training events.
  369. Analysis of patient records in family planning centers and its benefit to program management, final report. [Analyse des fiches de consultation des centres de planning familial en tant qu'outil de gestion du programme, rapport final.]
  370. Analyzing nurse-client interactions in family planning clinics.
  371. Andean seminar on research and family planning programs. [Seminario Andino de investigacion y servicios de planificacion familiar.]
  372. Anti-HIV efficacy of barrier contraceptives in HIV-discordant couples.
  373. Antibiotics and oral contraceptive pills.
  374. Antibiotics may pose dangers for contraceptive users and expectant mothers.
  375. Antiestrogen antibodies, oral contraception and systemic lupus erythematosus.
  376. Application of focus group discussion technique in understanding determinants of contraceptive use: a case study in Matlab, Bangladesh.
  377. Are contraceptive social marketing programs reaching their target markets?
  378. Assessing the impact of new contraceptive technologies on user satisfaction, use-dynamics, and service systems.
  379. Assessing the quality of family planning services in developing countries.
  380. An assessment of discrepancies between the Family Planning Logistics Management Information Systems and the Family Planning Performance Management Information Systems.
  381. Association of amoebae and Actinomyces in an intrauterine contraceptive device user.
  382. Asymptomatic salpingitis in intrauterine contraceptive device users.
  383. Attempts with lipanthyl to improve lipid metabolism during the adaptation period of women taking oral contraceptives.
  384. Background information from contraceptive behavior of abortion patients, indicating psychosocial factors leading to unwanted pregnancies. [Hintergrunde des Kontrazeptionsverhaltens von Abruptiopatientinnen als Hinweis auf psychosoziale Entstehungsbedingungen ungewollter Schwangerschaften.]
  385. Balance in family planning.
  386. Bangladesh family planning programme 1986.

     

  387. Carbohydrate metabolism in women using a triphasic oral contraceptive containing levonorgestrel and ethinylestradiol for six months. [Metabolisme glucidique chez des femmes sous contraceptif oral triphasique contenant du levonorgestrel et de l'ethinylestradiol pendant une periode de 6 mois.]
  388. Carbohydrate studies in women using a norethindrone triphasic oral contraceptive for eighteen months.
  389. Carcinoma of the cervix and oral contraceptives: epidemiological studies.
  390. Cardiovascular complications with the use of low-estrogen oral contraceptives in Finland 1974-1984.
  391. Cardiovascular effects of oral contraceptives: a review.
  392. Carl Stevens and his wife, Janice, have implemented an innovative family-planning program in India.
  393. A case of systemic lupus erythematosus after taking oral contraceptives.
  394. A case study of contraceptive introduction: domiciliary depot-medroxy progesterone acetate services in rural Bangladesh.
  395. In celebration of twenty years of legalizing family planning in Canada: proceedings of an International Meeting, held Wednesday, November 1, 1989, Ottawa, Ontario, Canada.
  396. The cervical cap. The rebirth of a contraception method.
  397. Changes in arterial blood pressure of women using hormonal contraceptives in relation to their cardiovascular history. [Izmeneniia arterialnogo davleniia vo vremia gormonalnoi kontratseptsii v zavisimosti ot osobennostei serdechno-sosudistogo anamneza zhenshchiny.]
  398. Changes in family planning and fertility in the Dominican Republic: relations and implications. [Los cambios en la planificacion familiar y la fecundidad en la Republica Dominicana. Relaciones e implicaciones.]
  399. Changes in the levels of precursors of endogenous synthesis of prostaglandins in intrauterine contraception. [Dinamika soderzhaniia predshestvennikov endogennogo sinteza prostaglandinov v protsesse vnutrimatochnoi kontratseptsii.]
  400. Changes of activities of some transferases, alkaline phosphatase and cholinesterase in the blood of women using oral contraceptives and in vitro influence of these agents on tissular enzyme levels in rat liver.
  401. Characteristics of family planning acceptors in Addis Ababa, Ethiopia.
  402. Characteristics of males at a public health department contraceptive service.
  403. Characteristics of successful distributors in the community-based distribution of contraceptives in Zaire.
  404. Characteristics of women at risk for pregnancy, who use no contraceptive method and reasons given for this. [Caracteristicas de mulheres com risco de engravidar, que nao usavam nenhum metodo contraceptivo e as razoes apresentadas para isto.]
  405. China to toughen its grip on birth control.
  406. China's expanding contraceptive range.
  407. China's family planning programme is advancing.
  408. China's nationwide fertility and family planning sample survey ends successfully.
  409. Chlamydia trachomatis cervical infection and oral contraceptive use among adolescent girls.
  410. Chlamydia trachomatis in a family planning unit. Prevalence, analysis of risk factors, prediction model. [Infection cervicale a Chlamydia trachomatis dans un centre de planning familial: prevalence, analyse des facteurs de risque, modele de prediction.]
  411. Choosing a contraceptive: method choice in Asia and the United States.
  412. Choosing the best oral contraceptive.
  413. Chorea as the initial presentation of oral contraceptive related systemic lupus erythematosus [letter]
  414. Cigarette smoking, alcohol, and oral contraceptive use by Type A adolescent -- the Bogalusa Heart Study.
  415. Clinical experience with a triphasic oral contraceptive containing ethinyloestradiol and levonorgestrel in Nigerian women.
  416. Clinical experience with an ethinyl estradiol-desogestrel oral contraceptive.
  417. Clinical experience with an injectable hormonal contraceptive in once-a-month doses in postabortal patients. [Experiencia clinica sobre un anticonceptivo hormonal inyectable en dosis unica mensual en pacientes post-aborto.]
  418. Clinical study on LRH-A contraception by luteolysis.
  419. A clinical trial and use of triziston-R as a contraceptive agent. [Klinichno izpitanie i prilozhenie na triziston-R kato protivozachatuchno sredstvo.]
  420. Clinical use of oral contraceptives administered vaginally: a case report.
  421. Clinicopathological problems of the local tissue effect of the copper-releasing intrauterine contraceptive device (IUD). I. General characteristics of the copper-containing IUD (clinical study)
  422. Colposcopic examination of the cervical epithelium during oral contraceptive use: a controlled clinical study. [Valutazione colposcopica degli epiteli cervicali in corso di contraccezione orale. Studio clinico controllato.]
  423. Combined oral contraceptives and liver cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives.
  424. Comment [on "Measuring Components of Family Planning Program Effort"]
  425. Commentary: family planning and sex education in STD.
  426. Communique of the National Sample Survey of Fertility and Birth Control (abstract)
  427. Community-based factors affecting contraceptive use patterns and discontinuation over the female reproductive life span: a preliminary anthropological assessment.
  428. Comparative endocrine pharmacodynamics of contraceptive steroids.
  429. Comparative evaluation of two once-a-month contraceptive injections.
  430. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women.
  431. Comparative studies of motivations for abortion and use of contraception by adolescent abortion patients. [Vergleichende Untersuchungen uber Motivationen zur Interruptio sowie zur Anwendung der Kontrazeption fur jugendliche Interruptiopatientinnen.]
  432. Comparison and fairness in family planning.
  433. Comparison of copper T-200 with Lippes Loop as a contraceptive device.
  434. A comparison of women's perceptions of Norplant contraceptive implants and NET contraceptive injections among 256 users in San Francisco.
  435. Complementing family planning with breastfeeding to improve child and maternal health: a comparative study of a rural and an urban slum population of Indonesia. Major findings from baseline data.
  436. Compliance and continuation of oral contraceptive acceptors in Magdalena, Colombia, 1986-87. Final report.
  437. Concerning the possibility of change in the role of the woman from object to subject of family planning. [Acerca de la posibilidad del cambio de la mujer como objeto a sujeto de la planificacion familiar.]
  438. Condom could be promoted as one of the best contraceptives in Indonesia.
  439. Condom promotion and use: family planning versus HIV protection.
  440. Consumers of oral contraceptives in a social marketing program in Honduras.
  441. Continuation and expansion of family planning operations research in Zaire, five year progress report.
  442. Continued use of contraception among clients in East Java, Indonesia.
  443. Continuities in the use of IUDs in patients using the family planning services of the Mexican Institute for Social Security. [La continuidad en el uso del DIU en poblacion usuaria de servicios de planificacion familiar del Seguro Social en Mexico.]
  444. Contraception and Gardnerella vaginalis. An initial study of the Italian population. [Contraccezione e Gardnerella vaginalis. Prima indagine sulla popolazione italiana.]
  445. Contraception and hepatogastroenterology. [Contraception et hepato-gastro-enterologie.]
  446. Contraception and irregular menses.
  447. Contraception and reproduction, health consequences for women and children in the developing world.
  448. Contraception and risk of genital infections in women. [Contraception et risque d'infections genitales chez la femme.]
  449. Contraception and the adolescent diabetic.
  450. Contraception and the climacteric. [Kontrazeption im Klimakterium.]
  451. Contraception for the diabetic woman: literature review. [Contraception chez la diabetique. Revue de la litterature.]
  452. Contraception in China.
  453. Contraception in China.
  454. Contraception in men: efficacy and immediate toxicity. A study of 18 cases.
  455. Contraception in Sweden.
  456. Contraception research.
  457. Contraception using intrauterine devices (IUDs). Indications, contraindications, risks. [Contraception par dispositifs intra-uterins. Indications, contre-indications, risques.]
  458. Contraception, control, and choice: international perspectives.
  459. Contraception.
  460. Contraception.
  461. Contraception: science and practice.
  462. Contraception: a general review. [Anti concepcao: uma visao geral.]
  463. Contraception: a general view. [Anticoncepcao: uma visao geral.]
  464. Contraception: rumors and reality. [Anticoncepcao: boatos e Realidade.]
  465. Contraception: short-term vs. long-term failure rates.
  466. Contraceptive and sexuality knowledge among inner-city middle school students from minority groups.
  467. Contraceptive behavior of abortion patients (editorial) [Kontrazeptionsverhalten von Abruptiopatientinnen.]
  468. Contraceptive behaviour in the areas served by family welfare assistants and midwives in rural Bangladesh: a comparative analysis.
  469. Contraceptive choice and use of health care in rural Mexico. [Elección de anticonceptivos y uso de servicios de atención de la salud en áreas rurales de México.]
  470. Contraceptive choice in the United States: process, determinants, and change.
  471. Contraceptive coverage after medical termination of pregnancy.
  472. Contraceptive development: the view from the United States in the mid-1980s.
  473. Contraceptive discontinuation in East Java, Indonesia.
  474. The contraceptive effectiveness of morrhuic acid suppository.
  475. Contraceptive efficacy of the Pill.
  476. The contraceptive gap.
  477. Contraceptive initiation patterns in Thailand.
  478. Contraceptive innovations: needs and opportunities.
  479. Contraceptive led to hysterectomy. Drug maker liable for side effects.
  480. The contraceptive method mix: an overview.
  481. Contraceptive methods and women's age. [Pratiques contraceptives et age des femmes.]
  482. Contraceptive methods for adolescents. [Metodos anticonceptivos para jovenes.]
  483. Contraceptive methods in the McCune-Albright syndrome.
  484. The contraceptive pill and breast cancer in young women.
  485. Contraceptive practice among women seeking legal abortion in the Scottish Highlands.
  486. Contraceptive practice in New Zealand [letter]
  487. Contraceptive practice in the Philippines.
  488. Contraceptive practice of Irish married and single first-time mothers.
  489. Contraceptive practices of patients referred for colposcopy with an abnormal cervical smear.
  490. Contraceptive practise of Thai women 1987. Results of the Study on Determinants and Consequences of Contraceptive Use Patterns in Thailand.
  491. Contraceptive prevalence in Jakarta, Indonesia: 1976-1983.
  492. Contraceptive problems unique to the United States.
  493. Contraceptive provision by commercial local agent distributors (the LADS project), final report.
  494. Contraceptive social marketing (CSM). POPTECH country reports confirm lessons learned in major worldwide study of contraceptive social marketing.
  495. Contraceptive social marketing principles: promoting condom use in Uganda and Tanzania for AIDS prevention.
  496. Contraceptive sterilization in Thailand.
  497. Contraceptive technology -- past, present and future.
  498. Contraceptive technology. [Tecnología anticonceptiva.]
  499. Contraceptive technology: international edition. Special Section on AIDS.
  500. Contraceptive trends in Great Britain.

To view other lists of the current category of articles, please visit "Category Lists Homepage"


Web PubHealth.info

© Copyrights PubHealth.info®, an information portal on public health. All rights reserved.

This page is optimized to be viewed by Java script enabled Microsoft® Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels.